Ontology highlight
ABSTRACT: Introduction
There is significant interest in the use of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) in coronavirus disease 2019 (COVID-19) and concern over potential adverse effects since these medications upregulate the severe acute respiratory syndrome coronavirus 2 host cell entry receptor ACE2. Recent studies on ACE-I and ARB in COVID-19 were limited by excluding outpatients, excluding patients by age, analyzing ACE-I and ARB together, imputing missing data, and/or diagnosing COVID-19 by chest computed tomography without definitive reverse transcription polymerase chain reaction (RT-PCR), all of which are addressed here.Methods
We performed a retrospective cohort study of 1023 COVID-19 patients diagnosed by RT-PCR at Stan
SUBMITTER: Rubin SJS
PROVIDER: S-EPMC7605244 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature